Phase I/II Dose-Escalation Trial of Daratumumab for Relapsed/Refractory Multiple Myeloma


Phase I/II Dose-Escalation Trial of Daratumumab for Relapsed/Refractory Multiple Myeloma
Slides from presentations at ASCO 2013/EHA 2013 and transcribed comments from a recent interview with Antonio Palumbo, MD (8/20/13)
Lokhorst HM et al. Daratumumab, a CD38 monoclonal antibody in patients with multiple myeloma — Data from the dose-escalation part of the FIH study. Proc ASCO 2013;Abstract 8512.

Lokhorst HM et al. Daratumumab, a CD38 monoclonal antibody study in advanced multiple myeloma — An open-label, dose escalation followed by open-label extension in a single-arm Phase I/II study. Proc EHA 2013;Abstract S576.

Dr Palumbo is Chief of the Myeloma Unit in the University of Torino’s Division of Hematology in Torino, Italy.